eli lilly lawsuit tirzepatide update https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Lilly asks to join lawsuit

This strongly suggests that the Biden team was not up to speed on GLP-1s in the first place, and was instead myopically focused on all things Ozempic (the name frequently used in the media when referring to semaglutide for weight loss, though this is actually the drugs brand name for its type 2 diabetes indication)

The implications of combining two unapproved or investigational compounds are significant

MHRA licensing, prescriber checks, common side effects, and how to avoid unregulated suppliers in the UK

Peptides like BPC-157 and TB-500 are blowing up online for injury recovery, but theyre not FDA-approved and theyre in a legal gray area

Amycretin is a unimolecular dual agonist of GLP-1 and amylin receptors a different approach from retatrutide's triple agonism